Your browser doesn't support javascript.
loading
The epidemiology of amyloidosis in Queensland, Australia.
Wisniowski, Brendan; McLeod, Donald S A; Adams, Rebecca; Harvey, Yasmin; Brown, Ian; McGuire, Lloyd; Armes, Jane; Mollee, Peter.
Affiliation
  • Wisniowski B; Pathology Queensland, Woolloongabba, Queensland, Australia.
  • McLeod DSA; School of Medicine, University of Queensland, Saint Lucia, Queensland, Australia.
  • Adams R; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Harvey Y; Pathology Queensland, Woolloongabba, Queensland, Australia.
  • Brown I; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • McGuire L; QML Pathology, Mansfield, Queensland, Australia.
  • Armes J; Sullivan Nicolaides Pathology, Bowen Hills, Queensland, Australia.
  • Mollee P; Envoi Pathology, Kelvin Grove, Queensland, Australia.
Br J Haematol ; 186(6): 829-836, 2019 09.
Article in En | MEDLINE | ID: mdl-31148162
ABSTRACT
Published studies on the epidemiology of amyloidosis have relied on death certificate data for case ascertainment. We estimated the incidence and mortality burden of amyloidosis among residents of the Australian state, Queensland, aged ≥20 years for the years 1999-2013 based on case ascertainment from histopathology reports. Information systems for participating laboratories were scrutinised to identify histopathology reports that documented a diagnosis of amyloidosis. Case mortality status was determined via linkage to the National Death Index. A total of 447 cases of amyloidosis were identified, with a median age at diagnosis of 66 years. A plasma cell dyscrasia was identified in 72% of patients who had paraprotein studies performed. The estimated incidence for Queenslanders aged ≥20 years was 12·1 cases per million person years. The median survival was 2·45 years. Age at diagnosis, presence of a paraprotein, earlier year of diagnosis, and inner regional location of residence (compared with residence in a major city) were independently associated with reduced survival. Our data confirms previously reported incidence data for amyloidosis of approximately 10 cases per million patient years and indicates that survival for Queensland patients with amyloidosis is improving, though it remains poor for the elderly and patients with AL amyloidosis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin Light-chain Amyloidosis Type of study: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Oceania Language: En Journal: Br J Haematol Year: 2019 Type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin Light-chain Amyloidosis Type of study: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Oceania Language: En Journal: Br J Haematol Year: 2019 Type: Article Affiliation country: Australia